Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.
da Costa-Rocha IA, Campi-Azevedo AC, Peruhype-Magalhães V, Coelho-Dos-Reis JG, Fradico JRB, Souza-Lopes T, Reis LR, Freire LC, Costa-Pereira C, Mambrini JVM, Maia MLS, de Lima SMB, de Noronha TG, Xavier JR, Camacho LAB, de Albuquerque EM, Farias RHG, de Castro TDM, Homma A, Romano APM, Domingues CM, Martins RM, Teixeira-Carvalho A, Martins-Filho OA. da Costa-Rocha IA, et al. Among authors: maia mls. Front Immunol. 2019 Jun 21;10:1211. doi: 10.3389/fimmu.2019.01211. eCollection 2019. Front Immunol. 2019. PMID: 31293563 Free PMC article. Clinical Trial.
Duration of post-vaccination immunity against yellow fever in adults.
Collaborative group for studies on yellow fever vaccines. Collaborative group for studies on yellow fever vaccines. Vaccine. 2014 Sep 3;32(39):4977-84. doi: 10.1016/j.vaccine.2014.07.021. Epub 2014 Jul 29. Vaccine. 2014. PMID: 25090646 Free article.
Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study.
Santos EMD, Noronha TG, Alves IS, Cruz RLS, Ferroco CLV, Brum RC, Oliveira PMN, Siqueira MM, Lima MC, Ramos FLP, Bragagnolo CM, Camacho LAB, Maia MLS. Santos EMD, et al. Among authors: maia mls. Mem Inst Oswaldo Cruz. 2019 Mar 7;114:e180517. doi: 10.1590/0074-02760180517. Mem Inst Oswaldo Cruz. 2019. PMID: 30843921 Free PMC article. Clinical Trial.
Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis.
Ferreira CC, Campi-Azevedo AC, Peruhype-Magalhāes V, Coelho-Dos-Reis JG, Antonelli LRDV, Torres K, Freire LC, da Costa-Rocha IA, Oliveira ACV, Maia MLS, de Lima SMB, Domingues CM, Teixeira-Carvalho A, Martins-Filho OA, da Mota LMH; Collaborative Group for Studies of Yellow Fever Vaccine. Ferreira CC, et al. Among authors: maia mls. Arthritis Res Ther. 2019 Mar 14;21(1):75. doi: 10.1186/s13075-019-1854-6. Arthritis Res Ther. 2019. PMID: 30871593 Free PMC article. Clinical Trial.
Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.
Campi-Azevedo AC, Reis LR, Peruhype-Magalhães V, Coelho-Dos-Reis JG, Antonelli LR, Fonseca CT, Costa-Pereira C, Souza-Fagundes EM, da Costa-Rocha IA, Mambrini JVM, Lemos JAC, Ribeiro JGL, Caldas IR, Camacho LAB, Maia MLS, de Noronha TG, de Lima SMB, Simões M, Freire MDS, Martins RM, Homma A, Tauil PL, Vasconcelos PFC, Romano APM, Domingues CM, Teixeira-Carvalho A, Martins-Filho OA. Campi-Azevedo AC, et al. Among authors: maia mls. Front Immunol. 2019 Sep 26;10:2192. doi: 10.3389/fimmu.2019.02192. eCollection 2019. Front Immunol. 2019. PMID: 31616412 Free PMC article. Clinical Trial.
Corrigendum: Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.
da Costa-Rocha IA, Campi-Azevedo AC, Peruhype-Magalhães V, Coelho-Dos-Reis JG, Fradico JRB, Souza-Lopes T, Reis LR, Freire LC, Costa-Pereira C, Mambrini JVM, Maia MLS, de Lima SMB, de Noronha TG, Xavier JR, Camacho LAB, de Albuquerque EM, Farias RHG, de Castro TDM, Homma A, Romano APM, Domingues CM, Martins RM, Teixeira-Carvalho A, Martins-Filho OA. da Costa-Rocha IA, et al. Among authors: maia mls. Front Immunol. 2019 Oct 22;10:2433. doi: 10.3389/fimmu.2019.02433. eCollection 2019. Front Immunol. 2019. PMID: 31695694 Free PMC article.
Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study.
Valim V, Machado KLLL, Miyamoto ST, Pinto AD, Rocha PCM, Serrano EV, Dinis VG, Gouvêa SA, Dias JGF, Campi-Azevedo AC, Teixeira-Carvalho A, Peruhype-Magalhães V, da Costa-Rocha IA, de Lima SMB, Miranda EH, Trindade GF, Maia MLS, Gavi MBRO, da Silva LB, Duque RH, Gianordoli APE, Casagrande TZ, Oliveira KG, Moura BCDM, Nicole-Batista F, Rodrigues LC, Clemente TB, Magalhães ES, Bissoli MF, Gouvea MDPG, Pinto-Neto LFDS, Costa CZ, Giovelli RA, Brandão LR, Polito ETL, Koehlert IO, Borjaille BP, Pereira DB, Dias LH, Merlo DL, Genelhu LFF, Pretti FZ, Giacomin MDS, Burian APN, Fantinato FFST, Pileggi GS, da Mota LMH, Martins-Filho OA. Valim V, et al. Among authors: maia mls. Front Immunol. 2020 Jul 17;11:1382. doi: 10.3389/fimmu.2020.01382. eCollection 2020. Front Immunol. 2020. PMID: 32765496 Free PMC article.
Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha.
da Silva AMV, Alvarado-Arnez LE, Azamor T, Batista-Silva LR, Leal-Calvo T, Bezerra OCL, Ribeiro-Alves M, Kehdy FSG, Neves PCDC, Bayma C, da Silva J, de Souza AF, Muller M, de Andrade EF, Andrade ACM, Dos Santos EM, Xavier JR, Maia MLS, Meireles RP, Cuni HN, Sander GB, Picon PD, Matos DCS, Moraes MO. da Silva AMV, et al. Among authors: maia mls. Front Cell Infect Microbiol. 2021 Jul 7;11:656393. doi: 10.3389/fcimb.2021.656393. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 34307188 Free PMC article.
26 results